Maria Chiara Buscarinu

List of Publications by Year
in descending order

67	2,145	304368 22	253896 43
papers	citations	h-index	g-index

70	70	70	3544
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. Multiple Sclerosis Journal, 2022, 28, 1034-1040.	1.4	37
2	Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study. Journal of Neurology, 2022, 269, 1610-1617.	1.8	7
3	The effect of air pollution on COVIDâ€19 severity in a sample of patients with multiple sclerosis. European Journal of Neurology, 2022, 29, 535-542.	1.7	8
4	Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study. Journal of Neurology, 2022, 269, 3301-3307.	1.8	9
5	Late-Onset MS: Disease Course and Safety-Efficacy of DMTS. Frontiers in Neurology, 2022, 13, 829331.	1.1	19
6	Multiple sclerosis genetic and non-genetic factors interact through the transient transcriptome. Scientific Reports, 2022, 12, 7536.	1.6	4
7	Anti-SARS-CoV-2 T-stem cell memory persists in ocrelizumab-treated MS patients. Multiple Sclerosis Journal, 2022, 28, 1937-1943.	1.4	6
8	Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study. European Journal of Neurology, 2021, 28, 1299-1307.	1.7	12
9	Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis. Journal of Neurology, 2021, 268, 2238-2245.	1.8	15
10	Operationalization of a frailty index in patients with multiple sclerosis: A cross-sectional investigation. Multiple Sclerosis Journal, 2021, 27, 1939-1947.	1.4	13
11	Diseaseâ€Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Annals of Neurology, 2021, 89, 780-789.	2.8	370
12	Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study. Journal of Neurology, 2021, 268, 2922-2932.	1.8	18
13	A Case of Double Standard: Sex Differences in Multiple Sclerosis Risk Factors. International Journal of Molecular Sciences, 2021, 22, 3696.	1.8	12
14	Circulating hsa-miR-323b-3p in Huntington's Disease: A Pilot Study. Frontiers in Neurology, 2021, 12, 657973.	1.1	11
15	A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgia. Journal of the Neurological Sciences, 2021, 424, 117430.	0.3	1
16	MAIT Cells and Microbiota in Multiple Sclerosis and Other Autoimmune Diseases. Microorganisms, 2021, 9, 1132.	1.6	14
17	DMTs and Covidâ€19 severity in MS: a pooled analysis from Italy and France. Annals of Clinical and Translational Neurology, 2021, 8, 1738-1744.	1.7	86
18	Intestinal Permeability and Circulating CD161+CCR6+CD8+T Cells in Patients With Relapsingâ€“Remitting Multiple Sclerosis Treated With Dimethylfumarate. Frontiers in Neurology, 2021, 12, 683398.	1.1	5

#	Article	IF	Citations
19	Multiple Sclerosis and SARS-CoV-2: Has the Interplay Started?. Frontiers in Immunology, 2021, 12, 755333.	2.2	33
20	Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. EBioMedicine, 2021, 72, 103581.	2.7	184
21	GWAS-associated variants, non-genetic factors, and transient transcriptome in multiple sclerosis etiopathogenesis: A colocalization analysis. Journal of the Neurological Sciences, 2021, 429, 118157.	0.3	0
22	Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study. Multiple Sclerosis and Related Disorders, 2020, 37, 101461.	0.9	14
23	Exit strategies for â€œneedle fatigueâ€•in multiple sclerosis: a propensity score-matched comparison study. Journal of Neurology, 2020, 267, 694-702.	1.8	6
24	EBV-specific CD8 T lymphocytes and B cells during glatiramer acetate therapy in patients with MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e876.	3.1	6
25	Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems group. Multiple Sclerosis and Related Disorders, 2020, 45, 102394.	0.9	2
26	Disentangling the molecular mechanisms of multiple sclerosis: The contribution of twin studies. Neuroscience and Biobehavioral Reviews, 2020, 111, 194-198.	2.9	7
27	Reworking GWAS Data to Understand the Role of Nongenetic Factors in MS Etiopathogenesis. Genes, 2020, 11, 97.	1.0	4
28	Informing MS patients on treatment options: a consensus on the process of consent taking. Neurological Sciences, 2020, 41, 2249-2253.	0.9	0
29	SARS-CoV-2 meta-interactome suggests disease-specific, autoimmune pathophysiologies and therapeutic targets. F1000Research, 2020, 9, 992.	0.8	10
30	Drug Holiday of Interferon Beta 1b in Multiple Sclerosis: A Pilot, Randomized, Single Blind Study of Non-inferiority. Frontiers in Neurology, 2019, 10, 695.	1.1	5
31	Autoimmune Encephalitis and CSF Anti-GluR3 Antibodies in an MS Patient after Alemtuzumab Treatment. Brain Sciences, 2019, 9, 299.	1.1	7
32	The Contribution of Gut Barrier Changes to Multiple Sclerosis Pathophysiology. Frontiers in Immunology, 2019, 10, 1916.	2.2	39
33	Conversion to Secondary Progressive Multiple Sclerosis: Patient Awareness and Needs. Results From an Online Survey in Italy and Germany. Frontiers in Neurology, 2019, 10, 916.	1.1	21
34	A cell type-specific transcriptomic approach to map B cell and monocyte type I interferon-linked pathogenic signatures in Multiple Sclerosis. Journal of Autoimmunity, 2019, 101, 1-16.	3.0	12
35	Genome-Wide Multiple Sclerosis Association Data and Coagulation. Frontiers in Neurology, 2019, 10, 95.	1.1	7
36	A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study. Journal of Neurology, 2018, 265, 1174-1183.	1.8	23

#	Article	IF	Citations
37	Thymosin-Î±1 expands deficient IL-10-producing regulatory B cell subsets in relapsingâ€“remitting multiple sclerosis patients. Multiple Sclerosis Journal, 2018, 24, 127-139.	1.4	23
38	Intestinal Permeability in Relapsing-Remitting Multiple Sclerosis. Neurotherapeutics, 2018, 15, 68-74.	2.1	55
39	Bacille Calmette-GuÃ©rin (BCG) Vaccine in Neuroinflammation. , 2018, , 25-38.		0
40	No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. Journal of Neurology, 2018, 265, 2851-2860.	1.8	43
41	Analysis of coding and non-coding transcriptome of peripheral B cells reveals an altered interferon response factor (IRF)-1 pathway in multiple sclerosis patients. Journal of Neuroimmunology, 2018, 324, 165-171.	1.1	10
42	Abortion induces reactivation of inflammation in relapsing-remitting multipleÂsclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1272-1278.	0.9	10
43	Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study. CNS Drugs, 2018, 32, 963-970.	2.7	35
44	Fingolimod vs dimethyl fumarate in multiple sclerosis. Neurology, 2018, 91, e153-e161.	1.5	35
45	Leptomeningitis in a Person with Radiologically Isolated Syndrome and Latent Tuberculosis: A Case Report with Implications for Clinical Research. Journal of Medical Imaging and Case Reports, 2018, 02, .	0.1	0
46	Altered intestinal permeability in patients with relapsingâ€“remitting multiple sclerosis: A pilot study. Multiple Sclerosis Journal, 2017, 23, 442-446.	1.4	107
47	Chemical Elements and Oxidative Status in Neuroinflammation. , 2017, , 67-81.		0
48	A staged screening of registered drugs highlights remyelinating drug candidates for clinical trials. Scientific Reports, 2017, 7, 45780.	1.6	31
49	Evidence for Detrimental Cross Interactions between Reactive Oxygen and Nitrogen Species in Leberâ€™s Hereditary Optic Neuropathy Cells. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-9.	1.9	7
50	Eosinophilic gastroenteritis in a woman with multiple sclerosis on dimethyl fumarate. Neurology, 2016, 87, 952-953.	1.5	7
51	Geographic Population Structure in Epstein-Barr Virus Revealed by Comparative Genomics. Genome Biology and Evolution, 2016, 8, 3284-3291.	1.1	29
52	Interferonâ€Î²2 therapy specifically reduces pathogenic memory B cells in multiple sclerosis patients by inducing a FASâ€mediated apoptosis. Immunology and Cell Biology, 2016, 94, 886-894.	1.0	61
53	IFN-Î²2 Therapy Regulates TLR7-Mediated Response in Plasmacytoid Dendritic Cells of Multiple Sclerosis Patients Influencing an Anti-Inflammatory Status. Journal of Interferon and Cytokine Research, 2015, 35, 668-681.	0.5	10
54	Twin studies in multiple sclerosis: A meta-estimation of heritability and environmentality. Multiple Sclerosis Journal, 2015, 21, 1404-1413.	1.4	43

#	Article	IF	Citations
55	Epstein-Barr virus genetic variants are associated with multiple sclerosis. Neurology, 2015, 84, 1362-1368.	1.5	44
56	Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants. Nature Immunology, 2015, 16, 1174-1184.	7.0	296
57	IFN-Î² and multiple sclerosis: From etiology to therapy and back. Cytokine and Growth Factor Reviews, 2015, 26, 221-228.	3.2	28
58	Effects of Bacille Calmette-GuÃ©rin after the first demyelinating event in the CNS. Neurology, 2014, 83, 380-381.	1.5	2
59	Shared environmental effects on multiple sclerosis susceptibility: conflicting evidence from twin studies. Brain, 2014, 137, e287-e287.	3.7	3
60	Effects of Bacille Calmette-GuErin after the first demyelinating event in the CNS. Neurology, 2014, 83, 293-293.	1.5	1
61	CD28 ligation in the absence of TCR stimulation up-regulates IL-17A and pro-inflammatory cytokines in relapsing-remitting multiple sclerosis T lymphocytes. Immunology Letters, 2014, 158, 134-142.	1.1	36
62	Effects of Bacille Calmette-GuÃ©rin after the first demyelinating event in the CNS. Neurology, 2014, 82, 41-48.	1.5	128
63	Characterization of Epsteinâ€“Barr virus genotypes in multiple sclerosis through next generation sequencing approaches. Journal of Neuroimmunology, 2014, 275, 79.	1.1	0
64	B cell IRF1 pathway is dysregulated in multiple sclerosis. Journal of Neuroimmunology, 2014, 275, 1.	1.1	1
65	Intestinal permeability in multiple sclerosis. Journal of Neuroimmunology, 2014, 275, 54.	1.1	1
66	A â€œCandidate-Interactomeâ€•Aggregate Analysis of Genome-Wide Association Data in Multiple Sclerosis. PLoS ONE, 2013, 8, e63300.	1.1	66
67	Viruses and neuroinflammation in multiple sclerosis. , 0, , .		6